These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 24982655)

  • 1. Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.
    Roatt BM; Aguiar-Soares RD; Coura-Vital W; Ker HG; Moreira Nd; Vitoriano-Souza J; Giunchetti RC; Carneiro CM; Reis AB
    Front Immunol; 2014; 5():272. PubMed ID: 24982655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-an experimental study.
    Joshi J; Malla N; Kaur S
    Parasitol Int; 2014 Aug; 63(4):612-20. PubMed ID: 24747611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.
    Dayakar A; Chandrasekaran S; Kuchipudi SV; Kalangi SK
    Front Immunol; 2019; 10():670. PubMed ID: 31024534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunology of post-kala-azar dermal leishmaniasis (PKDL).
    Zijlstra EE
    Parasit Vectors; 2016 Aug; 9(1):464. PubMed ID: 27553063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-kala-azar dermal leishmaniasis patients.
    Sarraf NR; Mukhopadhyay S; Banerjee A; Das AK; Roy S; Chakrabarti S; Manna M; Saha P
    Acta Trop; 2021 Nov; 223():106086. PubMed ID: 34389331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview of Immunotherapeutic Approaches Against Canine Visceral Leishmaniasis: What Has Been Tested on Dogs and a New Perspective on Improving Treatment Efficacy.
    Gonçalves AAM; Leite JC; Resende LA; Mariano RMDS; Silveira P; Melo-Júnior OAO; Ribeiro HS; de Oliveira DS; Soares DF; Santos TAP; Marques AF; Galdino AS; Martins-Filho OA; Dutra WO; da Silveira-Lemos D; Giunchetti RC
    Front Cell Infect Microbiol; 2019; 9():427. PubMed ID: 31921703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature.
    Okwor I; Uzonna JE
    Immunotherapy; 2009 Sep; 1(5):765-76. PubMed ID: 20636022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leishmaniasis in Sudan. Visceral leishmaniasis.
    Zijlstra EE; el-Hassan AM
    Trans R Soc Trop Med Hyg; 2001 Apr; 95 Suppl 1():S27-58. PubMed ID: 11370250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
    Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
    J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
    Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.
    Zijlstra EE
    PLoS Negl Trop Dis; 2014; 8(11):e3258. PubMed ID: 25412435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the protective efficacy of second-generation vaccine along with standard antileishmanial drug in Leishmania donovani infected BALB/c mice.
    Joshi J; Kaur S
    Parasitology; 2014 Apr; 141(4):554-62. PubMed ID: 24618257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous vaccine therapy associated with half course of Miltefosine promote activation of the proinflammatory response with control of splenic parasitism in a hamster model of visceral leishmaniasis.
    Carvalho LM; Ferreira FC; Gusmão MR; Costa AFP; de Brito RCF; Aguiar-Soares RDO; Reis AB; Cardoso JMO; Carneiro CM; Roatt BM
    Curr Res Immunol; 2021; 2():194-201. PubMed ID: 35492387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic typing reveals monomorphism between antimony sensitive and resistant Leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India.
    Subba Raju BV; Gurumurthy S; Kuhls K; Bhandari V; Schnonian G; Salotra P
    Parasitol Res; 2012 Oct; 111(4):1559-68. PubMed ID: 22752721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a sandwich ELISA to detect Leishmania 40S ribosomal protein S12 antigen from blood samples of visceral leishmaniasis patients.
    Zhang WW; Ghosh AK; Mohamath R; Whittle J; Picone A; Lypaczewski P; Ndao M; Howard RF; Das P; Reed SG; Matlashewski G
    BMC Infect Dis; 2018 Oct; 18(1):500. PubMed ID: 30285653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
    Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
    mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis.
    Nico D; Martins Almeida F; Maria Motta J; Soares Dos Santos Cardoso F; Freire-de-Lima CG; Freire-de-Lima L; de Luca PM; Maria Blanco Martinez A; Morrot A; Palatnik-de-Sousa CB
    Front Immunol; 2018; 9():967. PubMed ID: 29867949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
    Schaut RG; Grinnage-Pulley TL; Esch KJ; Toepp AJ; Duthie MS; Howard RF; Reed SG; Petersen CA
    Vaccine; 2016 Oct; 34(44):5225-5234. PubMed ID: 27665354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine Development Against Leishmania donovani.
    Das A; Ali N
    Front Immunol; 2012; 3():99. PubMed ID: 22615707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.